Forbes April 12, 2021
John LaMattina

If there was a silver lining in the Covid-19 pandemic, it was the response of the biopharmaceutical industry in generating multiple new vaccines with unprecedented speed – vaccines that promise to bring a sense of normalcy to the world. Social media is awash with selfies of people getting vaccinated (myself included!) universally expressing thanks to the science and scientists that helped to make this happen. Furthermore, it is not unusual to see people get emotional when getting their first shot after more than a year of masks, isolation and, most regrettably, the loss of loved ones. The development of Covid-19 vaccines has been a stunning achievement.

Yet, just as we can see the end of the pandemic, numerous proposals are...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending, Public Health / COVID
AbbVie tries to reassure investors on Humira biosimilar threat
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
This Biotech Startup Aims To Speed Up Drug Testing On Animals
Scientists reveal new method that could reduce waste from drug manufacturing
ETH develops AI algorithm for drug discovery based on 3D protein surface

Share This Article